PepGen Inc. (PEPG)

NASDAQ: PEPG · IEX Real-Time Price · USD
11.39
+0.86 (8.12%)
Apr 22, 2024, 4:00 PM EDT - Market closed
8.12%
Market Cap 368.92M
Revenue (ttm) n/a
Net Income (ttm) -78.63M
Shares Out 32.39M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,369
Open 10.61
Previous Close 10.54
Day's Range 10.22 - 11.44
52-Week Range 3.72 - 17.51
Beta n/a
Analysts Strong Buy
Price Target 23.33 (+104.83%)
Earnings Date May 9, 2024

About PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-ED... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2022
Employees 64
Stock Exchange NASDAQ
Ticker Symbol PEPG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price forecast is $23.33, which is an increase of 104.83% from the latest price.

Price Target
$23.33
(104.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PepGen to Participate in Upcoming Investor Conferences

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

5 weeks ago - GlobeNewsWire

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

5 weeks ago - GlobeNewsWire

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 ...

6 weeks ago - GlobeNewsWire

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

7 weeks ago - GlobeNewsWire

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

2 months ago - GlobeNewsWire

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

2 months ago - GlobeNewsWire

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

3 months ago - GlobeNewsWire

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data -

3 months ago - GlobeNewsWire

PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 -

4 months ago - GlobeNewsWire

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

5 months ago - GlobeNewsWire

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and Canada - - Ended third quarter 2023 with cash and cash equivalents of $129.5 m...

5 months ago - GlobeNewsWire

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –

6 months ago - GlobeNewsWire

PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

7 months ago - GlobeNewsWire

PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) The U.S. Food and Drug Administration (FDA) granted Orpha...

8 months ago - GlobeNewsWire

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -

8 months ago - GlobeNewsWire

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

8 months ago - GlobeNewsWire

PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiate...

9 months ago - GlobeNewsWire

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

11 months ago - GlobeNewsWire

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...

11 months ago - GlobeNewsWire

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 -

1 year ago - GlobeNewsWire

PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNE...

1 year ago - GlobeNewsWire

PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...

1 year ago - GlobeNewsWire

PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

1 year ago - GlobeNewsWire

PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

1 year ago - GlobeNewsWire

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...

1 year ago - GlobeNewsWire